Craig brings to Asher Bio more than 31 years in the biopharmaceutical industry, including a variety of research, business, and commercial roles, and continues to be passionate about building great teams to enable translation of scientific innovation into benefits for patients. Craig currently serves as the C.E.O. and Acting Chairman of the Board of Asher Bio. Also, he serves on the Boards of Directors for Aridis Pharmaceuticals (NASDAQ: ARDS), Inipharm Inc., and the Northern California Chapter of the Leukemia and Lymphoma Society. Previously Craig was Chief Business Officer at Forty Seven Inc. (NASDAQ: FTSV) and served on the Board of Tobira Therapeutics (NASDAQ: TBRA).